A triple drug approach that blocks the KRAS pathway at three points eliminated pancreatic tumors and prevented resistance in ...
A new preclinical study in mice shows that precancerous cells in the pancreas can be eliminated before they have the chance to become tumors. Using an experimental therapy to target microscopic ...
Researchers found that treating precancerous pancreatic lesions with experimental KRAS inhibitors slowed tumor development and improved survival in mice, demonstrating the potential of intercepting ...
HIGHLIGHTSAmplia’s lead drug narmafotinib enhances the activity of kRAS inhibitors in multiple preclinical cancer models presented at US ...
PanMETAI combines AI and NMR metabolomics to detect early-stage pancreatic cancer from a blood sample, achieving 93 percent ...
More and more people are being diagnosed with pancreatic cancer. This disease is insidious, often only making itself known in the later stages. A medical expert is now warning about its further spread ...
Namodenoson (CF102), an investigational small-molecule A3 adenosine receptor (A3AR) agonist, has demonstrated favorable ...
The experimental drug is an ultrasensitive version of CAR-T therapies, which have already revolutionized the treatment of ...
Depleting a clotting protein from the liver may help slow pancreatic cancer, according to a new study conducted by a team of researchers at the Indiana University Melvin and Bren Simon Comprehensive ...
Cancer Grand Challenges, a global initiative co-founded by the National Cancer Institute in the US and Cancer Research UK, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results